Rather a derogatory posting. From little acorns big oak trees grow. They are proceeding in a logical manner and you start small. They know what they are doing, indeed the MD/CEO? was on the Neuren team when it was 10c on a good day and through their logical small start, methodical approach that stock went to $10+.
Whilst we are doing the GLP preliminary work The US Army Walter Reed Centre is undergoing testwork as well and we should get a readout before too long, And yes, WR use rat(s) as well. WR is the LEADING brain injury research Centre in the USA. A positive result from their prelim work will hold us in good stead for FDA approval to go to Phase 1/2. After all, who would disagree with the US Army ! As for funding, an all clear from WR and no GLP issues would I expectasily funding from the US Army and/ or other agencies in the USA. The US Army has said Traumatic Brain Injury is their Number 1 issue when it comes to medical research. The risk/reward scenarion here is too compelling to ignore.
- Forums
- ASX - By Stock
- NYR
- Ann: Brain Injury Program GLP Studies Further Update
Ann: Brain Injury Program GLP Studies Further Update, page-4
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NYR (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.2¢ |
Change
-0.009(14.8%) |
Mkt cap ! $10.02M |
Open | High | Low | Value | Volume |
5.8¢ | 5.8¢ | 5.2¢ | $12.47K | 222.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 16000 | 5.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.6¢ | 165000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 16000 | 0.051 |
1 | 10000 | 0.050 |
1 | 139744 | 0.045 |
1 | 100000 | 0.044 |
1 | 250020 | 0.040 |
Price($) | Vol. | No. |
---|---|---|
0.056 | 165000 | 1 |
0.058 | 83446 | 1 |
0.059 | 9534 | 1 |
0.061 | 150000 | 1 |
0.064 | 10000 | 1 |
Last trade - 14.05pm 26/08/2024 (20 minute delay) ? |
Featured News
NYR (ASX) Chart |